Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Orasure Tech Inc (OSUR)

Orasure Tech Inc (OSUR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 833,236
  • Shares Outstanding, K 62,066
  • Annual Sales, $ 154,610 K
  • Annual Income, $ 16,660 K
  • 60-Month Beta 0.45
  • Price/Sales 5.56
  • Price/Cash Flow 55.91
  • Price/Book 3.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.09
  • Prior Year 0.07
  • Growth Rate Est. (year over year) -228.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.46 +47.67%
on 06/24/20
14.46 -3.39%
on 07/13/20
+3.61 (+34.85%)
since 06/12/20
3-Month
9.46 +47.67%
on 06/24/20
18.27 -23.54%
on 05/11/20
+2.40 (+20.74%)
since 04/13/20
52-Week
5.23 +167.11%
on 03/13/20
18.27 -23.54%
on 05/11/20
+5.39 (+62.82%)
since 07/12/19

Most Recent Stories

More News
Look for Shares of Orasure Tech to Potentially Pullback after Yesterday's 6.40% Rise

Orasure Tech (NASDAQ:OSUR) traded in a range yesterday that spanned from a low of $13.42 to a high of $14.35. Yesterday, the shares gained 6.4%, which took the trading range above the 3-day high of $13.93...

OSUR : 13.97 (+4.06%)
Global Peptide Synthesis Market By Application, By Type, By Technology, By Product, By Type of Resin, By Labelling, By End-User, By Region, Competition, Forecast & Opportunities, 2025

Reportlinker.com announces the release of the report "Global Peptide Synthesis Market By Application, By Type, By Technology, By Product, By Type of Resin, By Labelling, By End-User, By Region, Competition,...

OSUR : 13.97 (+4.06%)
Greater Than AIDS, With Support From Walgreens and OraSure Technologies, to Provide 10,000 Free In-Home HIV Tests to Community Partners

With in-person health services limited due to COVID-19, Greater Than AIDS, a public information initiative of KFF, and Walgreens today announced a new program to provide 10,000 OraQuick(R) In-Home HIV...

WBA : 39.58 (-1.35%)
OSUR : 13.97 (+4.06%)
Diversigen, Inc. and Alimentiv Inc. Announce Collaboration Agreement for Ulcerative Colitis Research Study

Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ:OSUR), and Alimentiv Inc. (formerly Robarts Clinical Trials) today announced they have signed a collaboration agreement for a research...

OSUR : 13.97 (+4.06%)
Global HIV Self-test Kits Market Outlook to 2027 - Drivers, Restraints, Opportunities & Threats

, /PRNewswire/ -- The report has been added to offering.

OSUR : 13.97 (+4.06%)
RubrYc Therapeutics To Present at AACR Virtual Conference

RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies to improve outcomes for cancer and serious autoimmune disease patients, today announced the presentation...

OSUR : 13.97 (+4.06%)
Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic(TM) Oncology Product Candidate for HPV-Positive Cancers, at the American Association of Cancer Research Virtual Annual Meeting II

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced...

OSUR : 13.97 (+4.06%)
RUBY : 5.74 (-3.85%)
Orasure Tech Falls 1.05% on Heavy Volume: Watch For Potential Rebound

Orasure Tech (NASDAQ:OSUR) traded in a range yesterday that spanned from a low of $10.04 to a high of $10.48. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $10.15...

OSUR : 13.97 (+4.06%)
Metabolon, Inc. and DNA Genotek Collaborate on First Ambient-Temperature Microbiome Sampling Solution for Metabolomics

, /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomics, and DNA Genotek, a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), have collaborated to bring OMNImet™·GUT, the first...

OSUR : 13.97 (+4.06%)
OraSure's DNA Genotek Subsidiary Unveils First In-Home Self-Collection Device for Metabolomics

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services is introducing the first and only commercially...

OSUR : 13.97 (+4.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade OSUR with:

Business Summary

OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well...

See More

Key Turning Points

2nd Resistance Point 14.99
1st Resistance Point 14.48
Last Price 13.97
1st Support Level 13.44
2nd Support Level 12.91

See More

52-Week High 18.27
Last Price 13.97
Fibonacci 61.8% 13.29
Fibonacci 50% 11.75
Fibonacci 38.2% 10.21
52-Week Low 5.23

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar